psalexa
logo

T-Cell Immunotherapy Pipeline Analysis

Global T-Cell Immunotherapy Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: January 2017
Report Code: LS10766
Available Format:
Pages: 309

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Scope and Methodology

1.1 Research Scope

1.2 Research Methodology and Sources

Chapter 2. Executive Summary

2.1 Key Findings

2.2 Research Summary

Chapter 3. Pipeline Outlook

3.1 Overview

3.2 T-Cell Immunotherapy Pipeline Analysis

3.2.1 Pipeline Analysis by Target

3.2.2 Pipeline Analysis by Molecule Type

3.2.3 Pipeline Analysis by Route of Administration

3.2.4 Pipeline Analysis by Company

Chapter 4. Global T-Cell Immunotherapy Pipeline Analysis by Phase (2016)

4.1 Phase II: Drug profiles

4.1.1 Pre-Clinical Study

4.1.2 Pre-Clinical Results

4.1.3 Clinical Trials

4.1.4 Clinical Results

4.1.5 Strategic Development

4.1.6 Designation

4.1.7 Grants

4.1.8 Patent

4.1.9 Technology

4.2 Phase I: Drug profiles

4.2.1 Pre-Clinical Study

4.2.2 Pre-Clinical Results

4.2.3 Clinical Trials

4.2.4 Clinical Results

4.2.5 Strategic Development

4.2.6 Designation

4.2.7 Grants

4.2.8 Patent

4.2.9 Technology

4.3 Phase 0: Drug profiles

4.3.1 Pre-Clinical Study

4.3.2 Pre-Clinical Results

4.3.3 Clinical Trials

4.3.4 Clinical Results

4.3.5 Strategic Development

4.3.6 Designation

4.3.7 Grants

4.3.8 Patent

4.3.9 Technology

4.4 IND Filed: Drug profiles

4.4.1 Pre-Clinical Study

4.4.2 Pre-Clinical Results

4.4.3 Strategic Development

4.4.4 Designation

4.4.5 Grants

4.4.6 Patent

4.4.7 Technology

4.5 Pre-Clinical: Drug profiles

4.5.1 Pre-Clinical Study

4.5.2 Pre-Clinical Results

4.5.3 Strategic Development

4.5.4 Designation

4.5.5 Grants

4.5.6 Patent

4.5.7 Technology

4.6 Discovery: Drug profiles

4.6.1 Strategic Development

4.6.2 Designation

4.6.3 Grants

4.6.4 Patent

4.6.5 Technology

Chapter 5 SWOT Analysis of T-Cell Immunotherapy Pipeline

Chapter 6 Company Profiles

6.1 Business Overview

6.2 Product and Service Offerings

Chapter 7 Appendix

7.1 Abbreviations

LIST OF TABLES

SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

NUMBER OF WORLDWIDE DEATHS DUE TO DIFFERENT CANCER

GLOBAL T-CELL IMMUNOTHERAPY PIPELINE SPLIT, BY COMPANY (2016)

DESCRIPTION OF PHASE II DRUGS

CLINICAL TRIALS OF PHASE II DRUGS

DESCRIPTION OF PHASE I DRUGS

CLINICAL TRIALS OF PHASE I DRUGS

DESCRIPTION OF PHASE 0 DRUGS

CLINICAL TRIALS OF PHASE 0 DRUGS

DESCRIPTION OF IND FILED DRUGS

DESCRIPTION OF PRE-CLINICAL DRUGS

DESCRIPTION OF DISCOVERY DRUGS

SWOT ANALYSIS OF T-CELL IMMUNOTHERAPY

COMPANIES- AT A GLANCE

 

LIST OF FIGURES

GLOBAL INCIDENCE OF CANCER (2015)

NUMBER OF PRODUCTS OF T-CELL IMMUNOTHERAPY UNDER DEVELOPMENT (2016)

GLOBAL T-CELL IMMUNOTHERAPY PIPELINE SPLIT, BY TARGET (2016)

GLOBAL T-CELL IMMUNOTHERAPY PIPELINE SPLIT, BY MOLECULE TYPE (2016)

GLOBAL T-CELL IMMUNOTHERAPY PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2016) 

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 4000
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 5000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 8000

Pre-Purchase Enquiry